EXEL: Exelixis, Inc.
About
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Current Value
$34.571 Year Return
Current Value
$34.571 Year Return
Key Details
Market Cap
$9.83B
P/E Ratio
21.93
1Y Stock Return
62.16%
1Y Revenue Growth
17.31%
Dividend Yield
0.00%
Price to Book
4.3
Strategies that include EXEL
Stock's related to EXEL
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SUPN | 40.21% | $1.96B | +30.48% | 0.00% |
| HURN | 34.10% | $2.13B | +14.70% | 0.00% |
| KRNT | 33.97% | $1.48B | +73.34% | 0.00% |
| VCYT | 33.76% | $3.03B | +55.48% | 0.00% |
| BRSP | 33.61% | $806.64M | -3.86% | 12.20% |
| NGVT | 33.09% | $1.67B | +18.26% | 0.00% |
| DGX | 32.04% | $17.99B | +19.98% | 1.84% |
| DVAX | 31.64% | $1.58B | -11.37% | 0.00% |
| RVLV | 31.41% | $2.35B | +127.64% | 0.00% |
| SWI | 31.14% | $2.22B | +22.97% | 0.00% |
| NRDS | 31.10% | $984.08M | +21.93% | 0.00% |
| BL | 30.89% | $3.61B | +3.02% | 0.00% |
| OMF | 30.75% | $6.51B | +43.89% | 7.52% |
| NJR | 30.32% | $4.83B | +16.85% | 3.54% |
| SMP | 30.12% | $690.97M | -10.09% | 3.65% |
| RYAM | 30.00% | $596.54M | +189.14% | 0.00% |
| FTNT | 29.95% | $69.59B | +72.67% | 0.00% |
| IVT | 29.84% | $2.38B | +27.45% | 2.91% |
| AXON | 29.51% | $46.53B | +167.14% | 0.00% |
| HHH | 29.35% | $3.98B | +14.89% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| QUAD | -<0.01% | $366.66M | +43.76% | 2.84% |
| AAOI | -0.03% | $1.29B | +114.18% | 0.00% |
| TXMD | -0.04% | $14.99M | -53.32% | 0.00% |
| RXST | -0.04% | $1.82B | +62.89% | 0.00% |
| CCJ | 0.07% | $25.01B | +28.34% | 0.15% |
| ALAB | 0.08% | $15.10B | +164.39% | 0.00% |
| HEAR | -0.08% | $300.79M | +44.04% | 0.00% |
| REAL | 0.08% | $473.87M | +93.72% | 0.00% |
| KTOS | 0.10% | $3.78B | +33.46% | 0.00% |
| DOGZ | -0.15% | $614.77M | +1,372.26% | 0.00% |
| STVN | -0.15% | $4.95B | -32.48% | 0.32% |
| TSCO | 0.16% | $29.15B | +38.19% | 1.59% |
| FICO | -0.17% | $55.62B | +116.55% | 0.00% |
| MU | 0.19% | $108.36B | +27.40% | 0.47% |
| ACHV | -0.22% | $149.25M | -17.65% | 0.00% |
| MODG | 0.23% | $1.56B | -25.89% | 0.00% |
| TRI | 0.27% | $72.33B | +16.06% | 1.01% |
| TOST | -0.27% | $24.14B | +207.53% | 0.00% |
| LC | -0.27% | $1.69B | +175.00% | 0.00% |
| IOSP | -0.27% | $2.91B | +9.50% | 1.32% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRTO | -24.81% | $2.10B | +58.23% | 0.00% |
| QRVO | -21.38% | $6.27B | -28.83% | 0.00% |
| CLW | -18.41% | $413.53M | -30.06% | 0.00% |
| ODP | -18.34% | $777.35M | -46.62% | 0.00% |
| CTMX | -18.24% | $69.86M | -31.59% | 0.00% |
| SMCI | -18.13% | $16.55B | -2.47% | 0.00% |
| ABNB | -18.07% | $82.12B | +3.64% | 0.00% |
| GFF | -17.94% | $3.64B | +64.52% | 0.77% |
| OPCH | -16.71% | $3.71B | -27.12% | 0.00% |
| WING | -16.37% | $9.80B | +45.66% | 0.29% |
| MAGN | -16.04% | $638.97M | -3.42% | 0.00% |
| LLY | -16.00% | $692.74B | +23.14% | 0.71% |
| SGC | -15.47% | $261.95M | +41.61% | 4.32% |
| TMDX | -15.46% | $2.78B | +22.14% | 0.00% |
| TREX | -15.27% | $7.22B | -0.22% | 0.00% |
| CRMD | -13.36% | $671.70M | +205.80% | 0.00% |
| ASML | -13.29% | $260.51B | -3.25% | 1.03% |
| ANAB | -13.27% | $607.66M | +40.93% | 0.00% |
| AZEK | -12.42% | $6.72B | +49.20% | 0.00% |
| CMG | -12.36% | $80.02B | +33.62% | 0.00% |
ETF's related to EXEL
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FBCG | 0.02% | $2.55B | 0.59% |
| IVW | 0.04% | $54.47B | 0.18% |
| FLRT | 0.06% | $401.26M | 0.6% |
| JGRO | -0.11% | $3.98B | 0.44% |
| FTEC | -0.11% | $12.59B | 0.084% |
| QYLD | -0.13% | $8.25B | 0.61% |
| GBIL | -0.13% | $5.60B | 0.12% |
| IWF | -0.15% | $101.63B | 0.19% |
| FLMI | 0.17% | $356.19M | 0.3% |
| HYD | 0.20% | $3.18B | 0.32% |
| IGM | 0.21% | $5.60B | 0.41% |
| VONG | -0.22% | $23.85B | 0.08% |
| VOOG | 0.23% | $13.96B | 0.1% |
| DBO | -0.26% | $217.57M | 0.77% |
| SOYB | 0.27% | $27.32M | 0.22% |
| HYMB | 0.30% | $2.81B | 0.35% |
| QQQM | 0.31% | $36.44B | 0.15% |
| MUST | -0.31% | $410.00M | 0.23% |
| SPMO | 0.32% | $3.92B | 0.13% |
| SCHG | -0.43% | $35.11B | 0.04% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| EQLS | -14.36% | $76.08M | 1% |
| SGOV | -13.43% | $27.53B | 0.09% |
| VIXY | -13.29% | $195.31M | 0.85% |
| IBMM | -13.17% | $391.28M | 0.18% |
| ICSH | -10.48% | $5.57B | 0.08% |
| PHDG | -10.12% | $113.97M | 0.39% |
| MINT | -9.05% | $11.62B | 0.35% |
| BTAL | -8.49% | $388.04M | 1.43% |
| SMH | -8.49% | $23.66B | 0.35% |
| FBY | -8.30% | $127.69M | 0.99% |
| IYW | -7.76% | $19.23B | 0.39% |
| VCAR | -7.71% | $9.00M | 1.2% |
| SOXQ | -7.66% | $490.35M | 0.19% |
| IXN | -7.62% | $5.14B | 0.41% |
| XLK | -7.51% | $71.43B | 0.09% |
| UUP | -7.39% | $309.25M | 0.77% |
| TBIL | -7.26% | $4.38B | 0.15% |
| WINN | -7.18% | $620.54M | 0.57% |
| AGZD | -7.07% | $142.76M | 0.23% |
| SOXX | -6.99% | $13.20B | 0.35% |
News
Yahoo
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Yahoo
A Relative Strength Rating upgrade for Vericel shows improving technical performance. Will it continue?
Yahoo
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Yahoo
ALAMEDA, Calif., November 07, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:
Yahoo
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Yahoo
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.